Company intelligence / Profile preview
ChainGen Bio
Shanghai, Shanghai, Chinalinkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ChainGen Bio develops proprietary technologies enabling targeted delivery of oligonucleotides beyond the liver using antibody and peptide-based transferrin receptor binding modules and site-specific bioconjugation. The company’s XOC platform aims to address the challenge of extrahepatic delivery for nucleic acid drugs. No clinical results have been reported as of June 2025.
- Therapeutic areas
- Other
- Modalities
- AntibodyPeptidesOligonucleotide conjugateSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Bioreainn Inc.GenScript ProBio
Beyond the preview
Go deeper on ChainGen Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChainGen Bio.